Tiba Biotech https://validator.w3.org/feed/docs/rss2.html Blog Vaccine Breakthrough for Global Livestock Diseases CEPI Partners with Tiba Biotech to Evaluate Next-Generation RNA Vaccine Platform Technology to Respond to ‘Disease X’ Our Team BARDA highlights Tiba Biotech in new FASTx program Tiba Biotech Receives NCI Grant to Advance Next-Generation RNA Cancer Immunotherapies History Home Novel Foot-and-Mouth Disease Vaccine Provides Full Protection in Cattle Study BARDA Partners with Tiba Biotech to Develop Innovative Therapeutics Against Influenza Technology About Us Senior Associate Scientist Tech Transfer Roundup: Tiba and CEPI Strategize Together On ‘Disease X’ Coup de pouce majeur pour les vaccins à ARNm ciblant la «maladie X» CEPI highlights progress toward a new generation of vaccines Major Boost for mRNA Vaccines Targeting ‘Disease X’ Next-Gen RNA Vaccine Technology Focuses on Disease X Footer CEPI Assessing Advanced RNA Nanoparticle Vaccine Conflict of Interest Policy NIH awards Tiba a Phase II SBIR grant to advance RNA vaccines against pandemic influenza Tiba Biotech Selected as a BLUE KNIGHT™ Company Multi-institute Research on Nasal Delivery of Tiba’s RNABL™ Nanoparticles Published in SCIENCE IMMUNOLOGY Tiba livestock vaccine manufactured in NSW for the first time NIH Extends Tiba’s CIVICs Collaboration on RNA Influenza Vaccine Development Team (Full Report) Channel Ten Sydney TV Reports on Private/Public Initiative to Address Emerging Animal Disease Threats in the Region A Shot in the Arm with 3D Printed Microneedle Patch Tiba Biotech and the Australian State of New South Wales Enter Partnership to Address Emergency Animal Disease Threats Tiba secures NIAID grant for an RNA-based multi-antigen vaccine for SARS-CoV-2 Scalable manufacturing for novel, painless vaccine delivery (Exclusive) A Foot and Mouth Disease mRNA Vaccine Deal Has Been Signed Between the NSW Government and US Company Tiba Biotech Contact Us Tiba joins in the CIVIC effort to develop a universal influenza vaccine Funding opportunity for novel mRNA vaccines for emerging tick-borne diseases RNA Design A third COVID-19 vaccine effort is quietly underway at Pitt Partnering Company NIH funding to advance Tiba’s pandemic influenza RNA vaccine candidate Teaming up with Tufts researchers to develop next generation vaccines Contact Tiba and KAUST collaborators secure award to advance a pan-betacoronavirus vaccine Christian Mandl delivers a presentation on the past, and future, of mRNA vaccines at the GVIRF 2021 Accordions & Tabs Terms of Use Google Maps Privacy Policy Location